Gonorrhea testing

Gonorrhea is diagnosed with a NAAT (nucleic acid amplification test), which detects bacterial DNA from a sample collected at any infected site. For genital infection, you give a urine sample or a vaginal, cervical or urethral swab — you can often self-collect. If you've had receptive anal or oral sex, site-specific rectal and throat swabs are the only way to detect infections at those sites; a urine test will miss them entirely. Gonorrhea and chlamydia are almost always run on the same sample. Most private labs and at-home kits offer NAAT testing with results in 1–3 days, and no appointment is required at most direct-access labs.

Yes — gonorrhea is curable, but only with the right antibiotic given at the right dose. The CDC-recommended treatment is a single 500 mg intramuscular injection of ceftriaxone (1 g if body weight is 150 kg or more). When this is administered correctly, it reliably clears genital and rectal gonorrhea; throat gonorrhea is somewhat harder to clear and requires a test-of-cure swab 1–2 weeks later. The key word is 'correctly' — the wrong drug, an incomplete course, or an oral substitute won't clear the infection and drives the resistance that makes gonorrhea harder to treat for everyone.

<em>Neisseria gonorrhoeae</em> has developed resistance to every antibiotic class previously used against it, including oral options. Fluoroquinolones (ciprofloxacin, levofloxacin) are no longer effective. Oral cephalosporins like cefixime have inadequate drug concentrations at the throat and are no longer recommended as first-line. Azithromycin-based regimens have been discontinued due to widespread resistance. The injectable ceftriaxone achieves drug concentrations that oral drugs cannot replicate — which is exactly why the current standard requires an injection rather than a pill. If you cannot receive an injection due to a true cephalosporin allergy, ask your provider about the CDC-recommended alternative (gentamicin plus azithromycin).

In men, gonorrhea typically produces a thick, yellow or yellow-green urethral discharge — often described as purulent, and more pronounced than the thinner, clearer discharge of chlamydia. This is the symptom that earned gonorrhea the name 'the drip.' In women, discharge may be increased or changed in color or consistency, but it's frequently indistinguishable from normal vaginal secretions — or absent altogether. Rectal infection may produce a small amount of discharge, but is usually found only on examination or by swab. Never rely on discharge characteristics to diagnose or rule out gonorrhea.

Yes — pharyngeal gonorrhea is common and is one of the most clinically important sites because it is almost always completely asymptomatic. Most people with throat gonorrhea have no sore throat, no swollen glands, and nothing to suggest an infection is present. It's detected only with a throat swab (NAAT), and it's particularly prevalent among men who have sex with men who practice receptive oral sex. Pharyngeal gonorrhea is also the most difficult site to treat — cure rates with ceftriaxone are lower at the throat than at genital sites, which is why a test-of-cure swab 7–14 days after treatment is recommended.

Wait at least 1–2 weeks after a possible exposure for a reliable result. <em>N. gonorrhoeae</em> needs time to establish a detectable infection — a NAAT can detect it within a few days in some cases, but testing in the first 24–72 hours risks a false-negative even if infection is present. If you test early and the result is negative but you have symptoms or a confirmed exposure, re-test at the 2-week mark. For routine screening after an unprotected encounter with no symptoms, testing at 1–2 weeks is appropriate.

Yes — and this is one of the most serious reasons to test and treat early. In women, untreated gonorrhea ascends from the cervix into the uterus and fallopian tubes, causing pelvic inflammatory disease (PID). PID causes tubal scarring that can partially or fully block the fallopian tubes — preventing fertilization (infertility) or allowing a fertilized egg to implant in the tube rather than the uterus (ectopic pregnancy, which is life-threatening). Studies suggest 10–15% of untreated women develop PID, and each subsequent infection multiplies the cumulative scarring risk. In men, untreated gonorrhea can cause epididymitis, which in severe cases can impair sperm function. Early treatment with ceftriaxone prevents these outcomes entirely.

Disseminated gonococcal infection (DGI) occurs when <em>N. gonorrhoeae</em> enters the bloodstream and spreads beyond the original infection site — affecting joints, skin and, rarely, the heart or brain. It develops in approximately 1–3% of untreated gonorrhea cases and is the most common cause of infectious arthritis in sexually active young adults. The classic presentation is a triad: migratory polyarthritis (pain and swelling that moves from joint to joint), dermatitis (pustular or hemorrhagic skin lesions, often on the hands and feet), and tenosynovitis (tendon-sheath inflammation). DGI can progress to septic arthritis in a single joint — which can permanently destroy cartilage if not treated promptly — and to endocarditis or meningitis in rare cases. It requires hospitalization and intravenous ceftriaxone.

For uncomplicated urogenital gonorrhea treated with ceftriaxone, a routine test-of-cure is not required if symptoms resolve — but the CDC strongly recommends re-testing at 3 months, because re-infection from an untreated partner is the most common reason gonorrhea comes back. For pharyngeal (throat) gonorrhea, a test-of-cure NAAT or culture at 7–14 days after treatment IS specifically recommended, because cure rates at the throat are lower than at genital sites even with ceftriaxone. If you still have symptoms 7 or more days after treatment, that requires clinical evaluation — it may be re-infection, a treatment failure or a different diagnosis.

Yes — and it's more common than most people expect. Being cured of gonorrhea gives you no immunity whatsoever: you can be re-infected the same day if you have sex with a partner who still has untreated gonorrhea. Re-infection from an untreated partner is, in fact, the most common reason gonorrhea seems to 'come back' after a confirmed course of ceftriaxone. True antibiotic treatment failure — meaning the drug didn't clear the infection — is rare when ceftriaxone is correctly administered, but it does occur and requires culture and sensitivity testing. The distinction matters because re-infection is treated with standard ceftriaxone, while true treatment failure requires investigation and a different approach.

Absolutely yes — and this is why asymptomatic gonorrhea drives the epidemic. <em>N. gonorrhoeae</em> colonizes mucous membranes regardless of whether symptoms develop, and the bacteria are shed in genital secretions, rectal fluid and saliva from infected throat tissue. Most rectal and throat infections, and roughly half of all genital infections in women, produce no symptoms — yet all of them are contagious. The absence of symptoms does not reduce transmissibility. This is the fundamental reason routine screening matters: most gonorrhea is transmitted by people who have no idea they're infected.

Yes — a newborn can contract gonorrhea from an infected parent during vaginal delivery. The resulting infection is called gonococcal ophthalmia neonatorum: gonorrhea colonizes the baby's eyes as it passes through an infected birth canal, causing a rapidly progressive purulent eye infection that can cause permanent corneal scarring and blindness within days if not treated with systemic ceftriaxone. This is why all newborns in the US routinely receive antibiotic eye drops (erythromycin ointment) at birth — but prophylaxis is not 100% effective and is not a substitute for prenatal testing and treatment. Screening at the first prenatal visit (and again in the third trimester for those at risk) is the primary safeguard for the baby.

Yes — substantially. Active gonorrheal infection increases both the risk of acquiring HIV during an exposure and the risk of transmitting HIV to a partner. The mechanism is biological: gonorrhea causes mucosal inflammation that disrupts the epithelial barrier, concentrates HIV-susceptible immune cells (CD4+ T-cells) at the site of infection, and amplifies HIV viral shedding in genital secretions. Studies suggest that active gonorrhea increases the per-act probability of HIV acquisition and transmission by approximately 2–5 times. This makes STI screening and treatment — including gonorrhea — an integral component of HIV prevention, not a separate concern.

Penicillin allergy does not automatically preclude ceftriaxone, which is a cephalosporin — a related but distinct antibiotic class. True immunological cross-reactivity between penicillin and cephalosporins is estimated at less than 2% in people with documented penicillin allergy, and most people who report penicillin allergy are not actually allergic on formal testing. If your allergy history suggests a high risk of cross-reaction (anaphylaxis, urticaria or severe prior penicillin reaction), discuss this with your provider — allergy evaluation or desensitization may be appropriate. For confirmed, severe cephalosporin allergy, the CDC-recommended alternative for gonorrhea is gentamicin 240 mg IM single dose plus azithromycin 2 g orally (note: azithromycin alone is not effective for gonorrhea).

Yes — gonorrhea can be transmitted through oral sex in multiple directions. The person giving oral sex can acquire pharyngeal (throat) gonorrhea from an infected genital or rectal area. The person receiving can acquire urethral or cervical gonorrhea from an infected mouth and throat. Pharyngeal gonorrhea is especially common in men who have sex with men who practice receptive oral sex, and it is almost universally asymptomatic — most people with throat gonorrhea have no sore throat or discomfort. Because condoms and dental dams are used less consistently for oral sex than for vaginal or anal sex, oral gonorrhea transmission is a significant and underappreciated route of spread. Site-specific throat swabs are the only way to detect it.